Multi-functional liposomes showing radiofrequency-triggered release and magnetic resonance imaging for tumor multi-mechanism therapy.
Recently, nanoplatforms with multiple functions, such as tumor-targeting drug carriers, MRI, optical imaging, thermal therapy etc., have become popular in the field of cancer research. The present study reports a novel multi-functional liposome for cancer theranostics. A dual targeted drug delivery with radiofrequency-triggered drug release and imaging based on the magnetic field influence was used advantageously for tumor multi-mechanism therapy. In this system, the surface of fullerene (C60) was decorated with iron oxide nanoparticles, and PEGylation formed a hybrid nanosystem (C60-Fe3O4-PEG2000). Thermosensitive liposomes (dipalmitoylphosphatidylcholine, DPPC) with DSPE-PEG2000-folate wrapped up the hybrid nanosystem and docetaxel (DTX), which were designed to combine features of biological and physical (magnetic) drug targeting for fullerene radiofrequency-triggered drug release. The magnetic liposomes not only served as powerful tumor diagnostic magnetic resonance imaging (MRI) contrast agents, but also as powerful agents for photothermal ablation of tumors. Furthermore, a remarkable thermal therapy combined chemotherapy multi-functional liposome nanoplatform converted radiofrequency energy into thermal energy to release drugs from thermosensitive liposomes, which was also observed during both in vitro and in vivo treatment. The multi-functional liposomes also could selectively kill cancer cells in highly localized regions via their excellent active tumor targeting and magnetic targeted abilities.
School of Pharmaceutical Sciences, Zhengzhou University, Science Road 100, 450001, Zhengzhou, China. zzzpaper@sina.com.
Bin
B
Du
Shuping
S
Han
Hongyan
H
Li
Feifei
F
Zhao
Xiangjie
X
Su
Xiaohui
X
Cao
Zhenzhong
Z
Zhang
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D003287:Contrast Media / Q000138:chemical synthesis; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000737:chemistry* / Q000528:radiation effects; D004058:Diffusion; D000077143:Docetaxel; D005260:Female; D037741:Fullerenes / Q000737:chemistry / Q000528:radiation effects; D008081:Liposomes / Q000008:administration & dosage / Q000737:chemistry* / Q000528:radiation effects; D061986:MCF-7 Cells; D008279:Magnetic Resonance Imaging / Q000379:methods*; D058185:Magnetite Nanoparticles / Q000737:chemistry / Q000528:radiation effects / Q000648:ultrastructure; D051379:Mice; D008810:Mice, Inbred C57BL; D053761:Nanocomposites / Q000528:radiation effects / Q000648:ultrastructure; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology*; D010778:Photochemotherapy / Q000379:methods; D011846:Radio Waves; D043823:Taxoids / Q000008:administration & dosage* / Q000737:chemistry; D000068936:Theranostic Nanomedicine / Q000379:methods
D000970:Antineoplastic Agents; D003287:Contrast Media; D003692:Delayed-Action Preparations; D037741:Fullerenes; D008081:Liposomes; D058185:Magnetite Nanoparticles; D043823:Taxoids; D000077143:Docetaxel; C069837:fullerene C60